HER2-Positive Advanced Breast Cancer
Conditions
Interventions
Patients diagnosed with HER2-positive advanced breast cancer (including locally advanced unresectable or metastatic disease):None
Sponsors
The First Affiliated Hospital of Wenzhou Medical University
Eligibility
Sex/Gender
Female
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Female patients aged >=18 years; 2. Newly diagnosed with HER2-positive recurrent/metastatic breast cancer between 2019 and 2024; 3. Histopathologically confirmed invasive breast cancer (AJCC 8th edition); 4. HER2-positive status (IHC 3+ or IHC 2+ with positive FISH testing); 5. Received first-line anti-HER2 targeted therapy in the advanced setting (PH dual-targeted therapy or TKI-containing regimens); 6. Complete baseline data, treatment records, and follow-up data for at least 2 months available; 7. Tumor tissue paraffin samples accessible (from primary tumor surgery or metastatic lesion biopsy).
Exclusion criteria
Exclusion criteria: 1. Presence of other malignancies; 2. Participation in prospective/interventional clinical trials.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Overall survival (OS); | — |
Secondary
| Measure | Time frame |
|---|---|
| Time to next treatment (TTNT);Objective response rate (ORR);Disease control rate (DCR);Progression-free survival (PFS); | — |
Countries
China
Contacts
Public ContactWang Ouchen
The First Affiliated Hospital of Wenzhou Medical University
Outcome results
None listed